Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Russo

Showing results (331-340 of 357) with videos related to

Pageof 36
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
European Urology Focus|July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell CarcinomaBrandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Scientific Reports|November 10, 2020
Evaluation of pathogen specific urinary peptides in tick-borne illnessesRuben Magni, Raghad Almofee, Sameen Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 TrialRobert J Motzer, Axel Bex, Paul Russo, et al.
Nature Communications|October 8, 2016
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsetsYing-Bei Chen, Jianing Xu, Anders Jacobsen Skanderup, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
European Urology Oncology|October 16, 2021
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic TestingHong Truong, Rania Sheikh, Ritesh Kotecha, et al.
JCI Insight|June 15, 2017
Genomic landscape and evolution of metastatic chromophobe renal cell carcinomaJozefina Casuscelli, Nils Weinhold, Gunes Gundem, et al.
Genome Medicine|December 19, 2022
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeMahdi Golkaram, Fengshen Kuo, Sounak Gupta, et al.
Pageof 36

Showing results (331-340 of 357) with videos related to

Sort By:
Pageof 36
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 30, 2020
Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease ProgressionJulian Marcon, Renzo G DiNatale, Alejandro Sanchez, et al.
European Urology Focus|July 30, 2017
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell CarcinomaBrandon John Manley, Emily C Zabor, Jozefina Casuscelli, et al.
Scientific Reports|November 10, 2020
Evaluation of pathogen specific urinary peptides in tick-borne illnessesRuben Magni, Raghad Almofee, Sameen Yusuf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 TrialRobert J Motzer, Axel Bex, Paul Russo, et al.
Nature Communications|October 8, 2016
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsetsYing-Bei Chen, Jianing Xu, Anders Jacobsen Skanderup, et al.
European Urology|November 5, 2025
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell CarcinomaMark T Dawidek, Lina Posada Calderon, Parantu K Shah, et al.
European Urology Oncology|October 16, 2021
Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic TestingHong Truong, Rania Sheikh, Ritesh Kotecha, et al.
JCI Insight|June 15, 2017
Genomic landscape and evolution of metastatic chromophobe renal cell carcinomaJozefina Casuscelli, Nils Weinhold, Gunes Gundem, et al.
Genome Medicine|December 19, 2022
Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escapeMahdi Golkaram, Fengshen Kuo, Sounak Gupta, et al.
Pageof 36